Moreover, the mean DTC number per patient was six times higher and the percentage of EpCAM+ DTCs was significantly higher in patients with metastatic cancer than in patients without metastases (66.53% vs. 8%). The gene discussed is EPCAM; the disease is metastatic malignant neoplasm.